Citations

Clear

3942 citation(s) found for "To, Van".

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
Steensma, David P. , Fenaux, Pierre , Eygen, Koen Van , Raza, Azra , Germing, Ulrich, Font, Patricia , Díez‐Campelo, María , Thépot, Sylvain , Vellenga, Edo , Patnaik, Mrinal M. , Jang, Jun Ho , Varsos, Helen, Bussolari, Jacqueline , Rose, Esther , Sherman, Laurie, Sun, Libo , Wan, Ying , Dougherty, Souria, Huang, Fei , Feller, Faye, Rizo, Aleksandra, Platzbecker, Uwe , Van Eygen, Koen , Font, Patricia , Thepot, Sylvain , Patnaik, Mrinal , Platzbecker, Uwe , Steensma, David P , Diez-Campelo, Maria , Santini, Valeria , Germing, Ulrich

Mayo Clinic

Journal of Clinical Oncology | November 19, 2020 | Volume: 39 | Issue: 1 | Pages: 48-56

10.1200/jco.20.01895 | PMID 33108243 Get It

PURPOSE Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC transfusion dependent and have experienced relapse after or are refractory to erythropoiesis-stimulating agent (ESA) have limited treatment options. High telomerase activity and human telomerase reverse-transcription expression in clonal hematopoietic cells have been reported in patients with MDS. Imetelstat, a first-in-class competitive inhibitor of telomerase enzymatic activity, targets cells with active telomerase. We report efficacy, safety, and biomarker data for patients with LR MDS who are RBC transfusion dependent and who were relapsed/refractory to ESAs. PATIENTS AND METHODS In this two-part phase II/III study (MDS3001), the primary end point was 8-week RBC transfusion independence (TI) rate, with key secondary end points of 24-week RBC TI rate, TI duration, and hematologic improvement-erythroid. RESULTS Data from the phase II part of the study are reported. Of 57 patients enrolled and treated (overall population), 38 were non-del(5q) and hypomethylating agent and lenalidomide naïve (subset population). The 8- and 24-week RBC TI rates in the overall population were 37% and 23%, respectively, with a median TI duration of 65 weeks. In the subset population, 8- and 24-week RBC TI rates were 42% and 29%, respectively, with a median TI duration of 86 weeks. Eight-week TI rate was observed across all subgroups evaluated. Cytogenetic and mutational data revealed a reduction of the malignant clones, suggesting disease modification activity. The most common adverse events were cytopenias, typically reversible within 4 weeks. CONCLUSION Imetelstat treatment results in a meaningful, durable TI rate across a broad range of heavily transfused patients with LR MDS who are ineligible for or relapsed/refractory to ESAs. Biomarker analyses indicated effects on the mutant malignant clone.
Method Limitations in LC-MS/MS and Immunonephelometric Measurement of IgG Subclasses
Gugten, Grace van der, Mattman, André , Ritchie, Gordon , Chen, Luke Y. C. , Chin, Alex , Mills, John R. , Rao, Lokinendi V. , Holmes, Daniel T.

Mayo Clinic

Clinical Chemistry | November 18, 2020 | Volume: 67 | Issue: 2 | Pages: 440-441

10.1093/clinchem/hvaa303 | PMID 33331942 Get It

A Potential Theragnostic Regulatory Axis for Arthrofibrosis Involving Adiponectin (ADIPOQ) Receptor 1 and 2 (ADIPOR1 and ADIPOR2), TGFβ1, and Smooth Muscle α-Actin (ACTA2)
Bayram, Banu , Owen, Aaron R. , Dudakovic, Amel , Dagneaux, Louis , Turner, Travis W., Bettencourt, Jacob W. , Limberg, Afton K. , Tibbo, Meagan E. , Berry, Daniel J., Kocher, Jean‐Pierre , Wijnen, André J. van , Berry, Daniel J. , Sanchez-Sotelo, Joaquin, Kocher, Jean-Pierre A , van Wijnen, Andre J , Berry, Daniel J , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Berry, Daniel J., Abdel, Matthew P.

Mayo Clinic

Journal of Clinical Medicine | November 17, 2020 | Volume: 9 | Issue: 11 | Pages: 3690

10.3390/jcm9113690 | PMID 33213041 Get It

(1) Background: Arthrofibrosis is a common cause of patient debility and dissatisfaction after total knee arthroplasty (TKA). The diversity of molecular pathways involved in arthrofibrosis disease progression suggest that effective treatments for arthrofibrosis may require a multimodal approach to counter the complex cellular mechanisms that direct disease pathogenesis. In this study, we leveraged RNA-seq data to define genes that are suppressed in arthrofibrosis patients and identified adiponectin (ADIPOQ) as a potential candidate. We hypothesized that signaling pathways activated by ADIPOQ and the cognate receptors ADIPOR1 and ADIPOR2 may prevent fibrosis-related events that contribute to arthrofibrosis. (2) Methods: Therefore, ADIPOR1 and ADIPOR2 were analyzed in a TGFβ1 inducible cell model for human myofibroblastogenesis by both loss- and gain-of-function experiments. (3) Results: Treatment with AdipoRon, which is a small molecule agonist of ADIPOR1 and ADIPOR2, decreased expression of collagens (COL1A1, COL3A1, and COL6A1) and the myofibroblast marker smooth muscle α-actin (ACTA2) at both mRNA and protein levels in basal and TGFβ1-induced cells. (4) Conclusions: Thus, ADIPOR1 and ADIPOR2 represent potential drug targets that may attenuate the pathogenesis of arthrofibrosis by suppressing TGFβ-dependent induction of myofibroblasts. These findings also suggest that AdipoRon therapy may reduce the development of arthrofibrosis by mediating anti-fibrotic effects in joint capsular tissues.
Polysaccharide from angelica sinensis attenuates SNP-Induced Apoptosis in osteoarthritis Chondrocytes by Inducing Autophagy via ERK1/2 Pathway
Zhuang, Chao, Li, Chenkai , Wang, Liangliang , Wang, Yuji , Xu, Chao , Ni, Su , Zhao, Gongyin , Jiang, Shijie , Zhu, Ruixia, Wijnen, André J. van

Mayo Clinic

No container title available | November 16, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-29285/v2 Get It

Abstract ObjectiveChondrocyte apoptosis plays a vital role in osteoarthritis (OA) progression. Angelica sinensis polysaccharide (ASP), a traditional Chinese medicine, possesses anti-inflammatory and anti-apoptotic properties in chondrocytes. This study aimed to determine the protective role of ASP on sodium nitroprusside (SNP)-induced chondrocyte apoptosis, and explore the underlying mechanism.MethodHuman primary chondrocytes isolated from articular cartilage of OA patients were treated with SNP alone or in combination with different doses of ASP. Cell viability and apoptosis were assessed, and apoptosis-related proteins including Bcl-2 and Bax were detected. Autophagy levels were evaluated by light chain 3 (LC3)-II immunofluorescence staining, mRFP-GFP-LC3 fluorescence localisation and western blot (LC3II, p62, Beclin-1, Atg5). Meanwhile,activation of ERK 1/2 pathway was determined by western blot. The autophagy inhibitors 3-Methyladenine (3-MA), chloroquine (CQ) and a specific inhibitor of ERK1/2, SCH772984, were used respectively to confirm the autophagic effect of ASP.ResultsThe results showed that SNP-induced chondrocyte apoptosis was significantly rescued by ASP, whereas ASP alone promoted chondrocytes proliferation. The anti-apoptotic effect of ASP was related to the enhanced autophagy and depended on the activation of ERK1/2 pathway.ConclusionASP markedly rescued SNP-induced chondrocyte apoptosis by activating ERK1/2-dependent autophagy in chondrocytes, and it made ASP a potential therapeutic supplementation for OA treatment.
Prospective Study of Disease-Specific Quality-of-Life in Sporadic Vestibular Schwannoma Comparing Observation, Radiosurgery, and Microsurgery
Carlson, Matthew L. , Barnes, Jason H. , Nassiri, Ashley M. , Patel, Neil , Tombers, Nicole M. , Lohse, Christine M. , Neff, Brian A., Driscoll, Colin L. W., Link, Michael J. , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | November 11, 2020 | Volume: 42 | Issue: 2 | Pages: e199-e208

10.1097/mao.0000000000002863 | PMID 33177408 Get It

Background: Previous cross-sectional studies analyzing quality of life (QOL) outcomes in patients with sporadic vestibular schwannoma (VS) have shown surprisingly little difference among treatment modalities. To date, there is limited prospective QOL outcome data available comparing baseline to posttreatment scores. Study Design: Prospective longitudinal study using the disease-specific Penn Acoustic Neuroma Quality of Life (PANQOL) scale. Setting: Large academic skull base center. Patients: Patients diagnosed with unilateral VS who completed a baseline survey before treatment and at least one posttreatment survey. Main Outcome Measures: Change in PANQOL scores from baseline to most recent survey. Results: A total of 244 patients were studied, including 78 (32%) who elected observation, 118 (48%) microsurgery, and 48 (20%) stereotactic radiosurgery. Patients who underwent microsurgery were younger (p < 0.001) and had larger tumors (p < 0.001) than those who underwent observation or radiosurgery; there was no significant difference in duration of follow-up among management groups (mean 2.1 yrs; p = 0.28). When comparing the total PANQOL score at baseline to the most recent survey, the net change was only –1.1, –0.1, and 0.3 points on a 100-point scale for observation, microsurgery, and radiosurgery, respectively (p = 0.89). After multivariable adjustment for baseline features, there were no statistically significant changes when comparing baseline to most recent scores within each management group for facial function, general health, balance, hearing loss, energy, and pain domains or total score. However, the microsurgical group experienced a 10.8-point improvement (p = 0.002) in anxiety following treatment, compared with 1.5 (p = 0.73) and 5.3 (p = 0.31) for observation and radiosurgery, respectively. Conclusions: In this prospective longitudinal study investigating differences in QOL outcomes among VS treatment groups using the disease-specific PANQOL instrument, treatment did not modify QOL in most domains. Microsurgery may confer an advantage with regard to patient anxiety, presumably relating to the psychological benefit of “cure” from having the tumor removed.
Working Toward Consensus on Sporadic Vestibular Schwannoma Care: A Modified Delphi Study
Carlson, Matthew L. , Link, Michael J., Driscoll, Colin L. W., Haynes, David S. , Billings, Heather , Lohse, Christine M. , Hall, Elissa R., Barker, Frederick G., Brackmann, Derald E., Cueva, Roberto A., Golfinos, John G. , Gurgel, Richard K. , Kondziolka, Douglas , Kutz, Joe Walter , Neff, Brian A., Sheehan, Jason P. , Yu, Chung Ping, Gurgel, Richard Klaus , Billings, Heather , Kondziolka, Douglas , Link, Michael J. , Agazzi, Siviero , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | November 9, 2020 | Volume: 41 | Issue: 10 | Pages: e1360-e1371

10.1097/mao.0000000000002917 | PMID 33492814 Get It

Objective:To address variance in clinical care surrounding sporadic vestibular schwannoma, a modified Delphi study was performed to establish a general framework to approach vestibular schwannoma care. A multidisciplinary panel of experts was established with deliberate representation from key stakeholder societies. External validity of the final statements was assessed through an online survey of registered attendees of the 8th Quadrennial International Conference on Vestibular Schwannoma.Study Design:Modified Delphi method.Methods:The panel consisted of 16 vestibular schwannoma experts (8 neurotology and 8 neurosurgery) and included delegates representing the AAOHNSF, AANS/CNS tumor section, ISRS, and NASBS. The modified Delphi method encompassed a four-step process, comprised of one prevoting round to establish a list of focus areas and three subsequent voting rounds to successively refine individual statements and establish levels of consensus. Thresholds for achieving moderate consensus, at ≥67% agreement, and strong consensus, at ≥80% agreement, were determined a priori. All voting was performed anonymously via the Qualtrics online survey tool and full participation from all panel members was required before procession to the next voting round.Results:Through the Delphi process, 103 items were developed encompassing hearing preservation (N = 49), tumor control and imaging surveillance (N = 20), preferred treatment (N = 24), operative considerations (N = 4), and complications (N = 6). As a result of item refinement, moderate (4%) or strong (96%) consensus was achieved in all 103 final statements. Seventy-nine conference registrants participated in the online survey to assess external validity. Among these survey respondents, moderate (N = 21, 20%) or strong (N = 73, 71%) consensus was achieved in 94 of 103 (91%) statements, and no consensus was reached in 9 (9%). Of the four items with moderate consensus by the expert panel, one had moderate consensus by the conference participants and three had no consensus.Conclusion:This modified Delphi study on sporadic vestibular schwannoma codifies 100% consensus within a multidisciplinary expert panel and is further supported by 91% consensus among an external group of clinicians who regularly provide care for patients with vestibular schwannoma. These final 103 statements address clinically pragmatic items that have direct application to everyday patient care. This document is not intended to define standard of care or drive insurance reimbursement, but rather to provide a general framework to approach vestibular schwannoma care for providers and patients.
ENSAT registry-based randomized clinical trials for adrenocortical carcinoma
Baudin, Éric , Chrisoulidou, Alexandra , Angelousi, Anna , Lamas, Cristina , Dijkum, Els J.�M. Nieveen van , Ceccato, Filippo , Tiberi, Guido A M, Ettaieb, Hester, Kiriakopoulos, Andreas , Kaštelan, Darko , Osher, Esthr, Yiannakopoulou, Eugenia , Arnaldi, Giorgio , Assié, Guillaume , Bourdeau, Isabelle , Newell‐Price, John , Nowak, Karolina M. , Romero, Mario, Martino, Maria Cristina De , Bugalho, Maria João , Dennedy, Michael Conall , Loli, Paula, Rodien, Patrice , Feelders, Richard A. , Aylwin, Simon , Morelli, Valentina , Vroonen, Laurent , Trofimiuk–Müldner, Małgorzata , Kroiß, Matthias , Mihai, Radu , Beuschlein, Felix , Ceccato, Filippo , Kroiss, Matthias , Dennedy, M Conall , Beuschlein, Felix , Newell-Price, John , Kastelan, Darko , Crona, Joakim , Terzolo, Massimo , Ronchi, Cristina L. , Borson‐Chazot, Françoise , Reimondo, Giuseppe , Canu, Letizia , Paiva, Isabel , Sherlock, Mark , Vantyghem, Marie‐Christine , Krijger, Ronald R. de , Slycke, Sam Van , Shafigullina, Zulfiya R. , Bancos, Irina , Quinkler, Marcus , Luconi, Michaela , Naruse, Mitsuhide , Igaz, Péter , Casa, Silvia Della , Berruti, Alfredo , Faßnacht, Martin

Mayo Clinic

European Journal of Endocrinology | November 9, 2020 | Volume: 184 | Issue: 2 | Pages: R51-R59

10.1530/eje-20-0800 | PMID 33166271 Get It

Adrenocortical carcinoma (ACC) is an orphan disease lacking effective systemic treatment options. The low incidence of the disease and high cost of clinical trials are major obstacles in the search for improved treatment strategies. As a novel approach, registry-based clinical trials have been introduced in clinical research, so allowing for significant cost reduction, but without compromising scientific benefit. Herein, we describe how the European Network for the Study of Adrenal Tumours (ENSAT) could transform its current registry into one fit for a clinical trial infrastructure. The rationale to perform randomized registry-based trials in ACC is outlined including an analysis of relevant limitations and challenges. We summarize a survey on this concept among ENSAT members who expressed a strong interest in the concept and rated its scientific potential as high. Legal aspects, including ethical approval of registry-based randomization were identified as potential obstacles. Finally, we describe three potential randomized registry-based clinical trials in an adjuvant setting and for advanced disease with a high potential to be executed within the framework of an advanced ENSAT registry. Thus we, therefore, provide the basis for future registry-based trials for ACC patients. This could ultimately provide proof-of-principle of how to perform more effective randomized trials for an orphan disease.
Shoulder magnetic resonance imaging findings in manual wheelchair users with spinal cord injury
Jahanian, Omid , Straaten, Meegan G. Van , Goodwin, Brianna M. , Lennon, Ryan J. , Barlow, Jonathan D. , Murthy, Naveen S. , Morrow, Melissa M. , Van Straaten, Meegan G , Morrow, Melissa M , Barlow, Jonathan D , Murthy, Naveen S , Jahanian, Omid

Mayo Clinic

The Journal of Spinal Cord Medicine | November 9, 2020 | Volume: 45 | Issue: 4 | Pages: 564-574

10.1080/10790268.2020.1834774 | PMID 33166207 Get It

Outcomes of Patients With Single-Node Metastasis of Human Papillomavirus–Related Oropharyngeal Cancer Treated With Transoral Surgery
Sinha, Parul , Last, Aisling, Ettyreddy, Abhinav R., Kallogjeri, Dorina , Pipkorn, Patrik , Rich, Jason T. , Zevallos, José P. , Paniello, Randal C., Abel, Katheryn Van, Moore, Eric J. , Oppelt, Peter , Palka, Kevin , Adkins, Douglas, Daly, Mackenzie, Abel, Kathryn M. Van , Van Abel, Katheryn, Van Abel, Kathryn M , Chen, Stephanie , Puram, Sid , Oppelt, Peter, Adkins, Douglas, Gay, Hiram A. , Thorstad, Wade , Jackson, Ryan S.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | November 5, 2020 | Volume: 147 | Issue: 1 | Pages: 16

10.1001/jamaoto.2020.3870 | PMID 33151273 Get It

Association of bone mineral density of the anterior cranial base, obesity, and spontaneous cerebrospinal fluid rhinorrhea
Low, Christopher M. , Kim, Dong Kun , Smith, Alyssa J. , Smith, Byron M., Stokken, Janalee K., O’Brien, Erin K. , Link, Michael J. , Yin, Linda X , O'Brien, Erin K , Choby, Garret , Yin, Linda X. , Gompel, Jamie J. Van , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | November 5, 2020 | Volume: 11 | Issue: 4 | Pages: 804-806

10.1002/alr.22717 | PMID 33151644 Get It